Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegeneration, Cardiovascular, and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MFG-E8/Medin drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human MFG-E8 (ECD-Fc / His Tag) / Medin Peptide High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View MFGE8 Products |
| Gene Delivery | MFG-E8 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. |
View MFGE8 Products |
| Benchmark Ab | Anti-MFG-E8 / Anti-Medin Recombinant Antibody Recombinant positive control for blocking and neutralization assays. |
View MFGE8 Products |
| Validator | MFG-E8 siRNA Set For knockdown verification in functional assays. |
View MFGE8 Products |
| Related Target A | ITGAV Integrin alpha V, key functional receptor partnering with MFG-E8 RGD motif. |
View ITGAV Products |
| Related Target B | TREM2 Microglial receptor regulating efferocytosis pathways synergistic with MFG-E8. |
View TREM2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Post-translational modifications (glycosylation) impact on Integrin binding | HEK293 mammalian expression host ensures native glycosylation and folding. |
| Medin peptide aggregation kinetics and consistency | Sequence verified, high-purity synthetic and recombinant Medin fragments with strict quality control. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live MFG-E8/Medin R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Milk Fat Globule-EGF Factor 8 (MFG-E8) and its cleavage product, Medin, represents a highly specialized frontier spanning immuno-oncology, cardiovascular disease, and neurodegeneration. MFG-E8 acts as a crucial bridging molecule for efferocytosis (the clearance of apoptotic cells) by binding to phosphatidylserine (PS) on dying cells and integrins ($\alpha_v\beta_3/\alpha_v\beta_5$) on phagocytes.
In oncology, MFG-E8 overexpression is associated with immune evasion, tumor angiogenesis, and resistance to therapy, making neutralizing antibodies a key area of study. Conversely, in neurodegenerative and vascular pathology, Medin—the 50-amino-acid peptide cleaved from the C2 domain of MFG-E8—has been identified as the most common amyloid in humans, aggregating in blood vessels and exacerbating Alzheimer's disease and vascular dementia. Consequently, the next wave of R&D is bifurcated: neutralizing MFG-E8/integrin interactions in solid tumors, and targeting Medin amyloid aggregates to preserve cerebrovascular function.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Anti-Medin) | Neurimmune, Academic Institutions | Alzheimer's Disease, Vascular Dementia | Aggregation inhibition & clearance assays (Need high-purity Medin peptide) |
| Monoclonal Antibody (Anti-MFG-E8) | Oncology-focused biotechs | Triple-Negative Breast Cancer, Prostate Cancer | Efferocytosis & Integrin-binding blockade (Need HEK293-expressed MFG-E8) |
| Recombinant Protein (MFG-E8) | Therapeutic developers (Inflammation) | Sepsis, Ischemia-Reperfusion Injury | Functional rescue assays (Need endotoxin-controlled recombinant MFG-E8) |